David A. Eichenbaum, MD, FASRS

New data show 8 mg aflibercept dries retinal fluid faster and lasts longer, enabling 12–16 week dosing in AMD, DME, and RVO.

Learn why newer anti‑VEGF options extend treatment for wet AMD, DME and RVO, signaling a shift from VEGF-only to multitarget therapy.

Experts weigh vision-first goals in retinal disease, debating dry OCT vs stable fluid, longer anti‑VEGF intervals, and next‑gen durable therapies.

Experts discuss balancing vision, dry retina goals, fluid tolerance, and longer-lasting anti-VEGF options to cut injection burden.

In this episode, “Diagnostic Imaging in Retinal Vascular Disease Management,” the panelists explore how recent innovations in multimodal imaging are transforming the diagnosis and management of retinal vascular diseases, including AMD, diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The expert faculty discuss the growing role of optical coherence tomography (OCT) as the foundational imaging modality in retina clinics and how additional technologies such as fundus autofluorescence, OCT angiography (OCTA), and ultra-widefield imaging are expanding clinicians’ ability to detect and monitor disease activity.

Welcome back to another Ophthalmology Times series. In this episode titled, “Advancing Care Across Retinal Vascular Diseases,” the expert faculty discussed the evolving management of retinal vascular diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The panel reviewed the significant prevalence and treatment burden associated with these chronic retinal conditions, emphasizing how frequently these diseases are encountered in clinical retina practice and the challenges associated with maintaining long-term patient adherence to therapy.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

David Eichenbaum, MD, FASRS, recalls an early-career case managing bilateral diabetic macular edema with frequent intravitreal triamcinolone injections—leading to severe steroid-induced glaucoma and valve implants.

From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption

Ophthalmologists reflect on the transformative impact of COVID-19, highlighting adaptations in patient care, safety protocols, and the rise of telemedicine.

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.

Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.

Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.

Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.

Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.